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Abstract
Diabetes, diarrhoea, renal failure and glucocorticoid therapy have all been identified as independent risk factors for
cataract. Increased post-translational modification of proteins, leading to inactivation of enzymes and induction of
conformational changes within proteins could result in lens opacification and cataract. Aspirin has been associated with
many beneficial effects, including protection against cataract, in-vivo. a-Crystallin has been shown to act as a molecular
chaperone in-vitro. This lenticular protein prevented the thermal aggregation of other lens proteins in-vitro and has sequence
 .and functional homology with the small heat shock proteins. Glyceraldehyde 3-phosphate dehydrogenase GAP-DH is
constitutively expressed in tissues and is susceptible to chemical modification in-vivo. In-vitro incubations of GAP-DH with
sugars, cyanate and prednisolone-21-hemisuccinate, all led to significant loss of enzyme activity with time in two buffer
systems. Rapid inactivation occurred when GAP-DH was incubated with fructose 6-phosphate or prednisolone-21-hemisuc-
cinate. Slower inactivation was observed when GAP-DH was incubated with fructose, glucose 6-phosphate or potassium
cyanate. Glucose did not inactivate GAP-DH under the conditions of our experiments. Aspirin and ibuprofen were shown to
inactivate GAP-DH very rapidly in-vitro. Bovine lenticular a-crystallin conferred no protection against GAP-DH inactiva-
tion. This is the first occasion that a-crystallin has been demonstrated to be unable to protect against inactivation in our
chemical enzyme inactivation system. This may have implications for the susceptibility of lenticular GAP-DH to
post-translational inactivation. q 1997 Elsevier Science B.V.
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1. Introduction
Evidence that increased levels of reactive small
molecules could be involved in the onset of a variety
of diseases has accumulated over the years. The
degree of glycation of haemoglobin may be used as a
w xmarker for diabetes 1 and rapid selective carbamyla-
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tion of this erythrocyte protein resulted from oral
administration of cyanate to patients with sickle cell
w xdisease 2 . Although such alterations may occur in
many cellular tissues, erythrocytes and especially the
lens offer ideal systems for studying post-transla-
tional modifications of proteins and their effects on
cellular homeostasis because both are largely denu-
cleated, therefore, proteins in these tissues are not
renewed and are long lived. Erythrocytes have a life
span of 120 days and are, thus, susceptible to envi-
0925-4439r97r$19.00 q 1997 Elsevier Science B.V. All rights reserved.
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w xronmental influences 1 . In the centre of the lens
 .lens nucleus , proteins may be as old as the individ-
ual itself and yet these proteins have to be extremely
stable in order to maintain the correct short range
order between proteins. Enzyme activities are also
w xdetectable in this region 3 and probably contribute
to the structural integrity of the lens. The mammalian
lens contains very high concentrations of a-, b- and
w xg-crystallins 4 . The interaction between these crys-
tallins and their differential distribution throughout
the lens helps maintain the transparency of the lens.
In other vertebrates, enzyme crystallins may replace
w xa-, b- and g-crystallins 5 . These crystallins have
evolved from enzymes and have been utilised by the
lens. In the diurnal gecko lens, glyceraldehyde 3-
 .phosphate dehydrogenase GAP-DH is found at such
high levels that it has been characterised as an en-
w xzyme crystallin 6 .
Sugars, glucocorticoids and cyanates can react with
free N-terminal a-amino groups or the «-amino
groups of lysine residues. This reaction can directly
inactivate an enzyme if it occurs at or near the active
site. Formation of adducts could induce conforma-
tional changes in proteins that destabilise the native
 .protein structure. GAP-DH EC 1.2.1.12 is an impor-
tant enzyme of glycolysis and is found at compara-
w xtively high levels in the lens 3 . In a variety of
diseases, the activities of several enzymes fall. The
activities of enzymes involved with energy
metabolism decreased in human muscle fibres of
chronic renal failure patients and glycation of ery-
throcyte superoxide dismutase increased in diabetes
w xand led to inactivation of the enzyme 7,8 . Enzyme
activities, including that of GAP-DH, are also de-
creased in experimentally induced cataracts and in
w xhuman diabetic cataract 9,4 . This is paralleled by
increased glycation of the human lens proteins of
w xdiabetics 10 or modification by glucocorticoids in
the case of patients who had undergone glucocorti-
w xcoid therapy 11 . Such chemical modifications can
w xproduce conformational changes 12 and this in addi-
tion to the accompanying inactivation of enzymes
may be the underlying common mechanism by which
cataract develops. The long lived lens proteins upon
exposure to highly elevated sugar, glucocorticoid or
cyanate levels that is seen with the onset of diabetes,
renal failure or as a consequence of glucocorticoid
therapy are an ideal target for such deleterious modi-
fications, as are erythrocyte proteins. Such a mecha-
nism may also be involved in diseases in nucleated
tissues such as diabetic retinopathy, nephropathy and
w xneuropathy 13,4 .
a-Crystallin, a major lens crystallin, has been
characterised as a molecular chaperone. It has se-
w xquence homology 14 and structural and functional
w xsimilarities to the small heat shock proteins 15 . Its
w xexpression is not confined to the lens 16 and is
w xelevated in a variety of diseased tissues 17 . Horwitz
has shown that a-crystallin prevents the in-vitro ther-
w xmally-induced aggregation of lens proteins 18 and
other groups have found that its chaperone properties
w xare temperature-dependent 19 and this may be re-
lated to structural transitions within the a-crystallin
w xaggregate itself 20 . Recently a-crystallin has been
shown to protect enzymes against sugar and steroid-
induced inactivation, protecting glucose 6-phosphate
w x w xdehydrogenase 21 , malate dehydrogenase 22 , glu-
w x w xtathione reductase 23 and catalase 24 against fruc-
tose- and prednisolone-21-hemisuccinate-induced in-
activation, respectively. Tsou has observed that in
incubation of GAP-DH and many other enzymes with
denaturants, inactivation preceded conformation
w xchange 25 . In-vivo, protection of enzyme activity by
a-crystallin may be a major mechanism by which the
lens maintains transparency.
Aspirin has been associated with many beneficial
effects in man ranging from protection against my-
ocardial infarction, Alzheimers disease and stroke to
w xcataract 26–28 . Aspirin and ibuprofen significantly
reduced the chemical modification of lens proteins
w xin-vitro 29,30 . In the case of aspirin, this may occur
by acetylation of lysine residues, thus, preventing
these lysines reacting with other small molecules
w xsuch as sugars 29 . Aspirin-like analgesics also de-
w xlayed the onset of diabetic cataract in rats 31,32 and
protected glutathione reductase against sugar-induced
w xinactivation in-vitro 33 .
In this communication, we show that fructose 6-
phosphate rapidly inactivated GAP-DH in-vitro.
Prednisolone-21-hemisuccinate, fructose, glucose 6-
phosphate and potassium cyanate inactivated less
rapidly. a-Crystallin failed to protect against both
steroid-induced and sugar-induced GAP-DH inactiva-
tion. The failure of a-crystallin to protect was shown
to be independent of both temperature and buffer
system. Aspirin-like analgesics, putative anti-cataract
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agents, inactivated GAP-DH in a very rapid manner.
These results suggest that GAP-DH may be suscepti-
ble to post-translational modifications at an early
stage during the onset of certain types of diseases.
2. Materials and methods
2.1. Materials
Potassium cyanate, rabbit muscle GAP-DH and
bakers yeast 3-phosphoglyceric phosphokinase, fruc-
tose, glucose, fructose 6-phosphate, glucose 6-phos-
phate, prednisolone-21-hemisuccinate and all other
chemicals were obtained from Sigma, Poole, Dorset,
U.K. Potassium cyanate was recrystallised before
being used.
2.2. Isolation of a-crystallin
a-Crystallin was isolated from bovine lenses by
gel chromatography on Sephacryl S-300 HR using
w xthe method of Slingsby and Bateman 34 . The a-
crystallin fraction was collected and its purity was
w xconfirmed by SDS–PAGE 35 .
2.3. Incubations of GAP-DH in triethanolamine buffer
at 328C
GAP-DH was initially suspended in double dis-
tilled water and then 800 ml aliquots were freeze
 .dried for experiments. GAP-DH 0.2 mgrml was
incubated in a shaking water bath, initially at 378C, at
which temperature GAP-DH was found to be very
labile, then at 328C, for most experiments, in 100 mM
triethanolamine buffer, 0.1 mM EDTA, pH 7.6 with
and without either fructose, glucose, fructose 6-phos-
phate, glucose 6-phosphate, potassium cyanate or
prednisolone-21-hemisuccinate at 1, 2, 5 or 10 mM
for between 4 and 24 h in a total final volume of
800 ml.
In some experiments, a-crystallin 40, 100 or
.1 mgrml was added to different vials during the
incubation. Alternatively, aspirin, paracetamol and
 .ibuprofen 10 mM were added to different vials.
Some solutions containing just GAP-DH and 10 mM
aspirin, paracetamol or ibuprofen were also set up
and compared to control incubations. This set of
experiments was repeated in 250 mM triethanolamine
buffer. Each solution was inoculated through 0.2 mM
sterile Whatman syringe filters into screw cap, auto-
claved sterile vials.
2.4. Incubations of catalase in sodium phosphate
buffer at 378C
To test whether a-crystallin chaperone activity
varied as a function of temperature we modified a
w xpreviously published protocol 24 . Catalase
 .25mgrml was incubated with or without 2 mM
prednisolone-21-hemisuccinate in the presence or ab-
 .sence of a-crystallin 40 mgrml at 328C as opposed
w xto 378C. Catalase was assayed at intervals as in 24 .
2.5. Incubations of GAP-DH in sodium phosphate
buffer at 378C
 .GAP-DH 1 mgrml was incubated in a shaking
water bath at 378C in 100 mM sodium phosphate
buffer, pH 7.6 with and without either fructose, glu-
cose, fructose 6-phosphate, glucose 6-phosphate,
potassium cyanate or prednisolone-21-hemisuccinate
at 1, 2, 5 or 10 mM in a total final volume of 800 ml.
In some experiments, a-crystallin 40, 100 mgrml
.or 1 mgrml was added to different vials.
2.6. GAP-DH assay
GAP-DH activity was assayed by monitoring the
decreased absorbance at 340 nm resulting from the
w xoxidation of NADH 36 for 1 min at 258C in a
coupled system with 3-phosphoglyceric phosphoki-
 .nase EC 2.7.2.3 . The assay mixture consisted of
2.48 ml of 0.1 M triethanolamine buffer, pH 7.6;
 .  82.3 mM D y -phosphoglyceric acid tri cyclohexy-
..lammonium ; 1.1 mM ATP, Na salt; 0.9 mM EDTA,
Na salt: 2 mM magnesium sulphate; 0.2 mM NADH,
Na salt; 2 ml 3-phosphoglyceric phosphokinase
 .7 Urml and 20 ml of incubation solution containing
 .GAP-DH 66 Urmg or 4.4 mUrml , resulting in a
final volume of 3 ml. In experiments involving incu-
bations in sodium phosphate buffer, sodium phos-
phate buffer replaced triethanolamine buffer in the
assay mixture. Unless otherwise stated, all assays
were carried out in triplicate and all experiments
were independently performed on three separate oc-
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casions. Activity is expressed relative to control ac-
tivity at each respective time interval, set at 100%,
unless otherwise stated.
2.7. High performance liquid chromatography
100 ml solutions incubated in sodium phosphate
buffer at 378C, containing 1 mgrml GAP-DH with or
without 5 mM fructose 6-phosphate or 2 mM pred-
nisolone-21-hemisuccinate in the absence or presence
of 3 mgrml a-crystallin, were removed at intervals
and centrifuged at 6850 g for 5 min. The upper 50 ml
of the solution was withdrawn and 30 ml of solution
was loaded onto a Biosep S4000 HPLC column and
eluted at 0.5 mlrh. Absorption at 280 nm was
recorded as a function of time.
2.8. Turbidity assay
 .GAP-DH 1 mgrml was incubated with 5 mM
fructose 6-phosphate or 2 mM prednisolone-21-
hemisuccinate in the absence or presence of 3 mgrml
bovine a-crystallin in 100 mM sodium phosphate
buffer, pH 7.6 in a shaking water bath at 378C. The
 .turbidity of solutions 1 ml was assayed at intervals
at 360 nm, over 8 h in the case of incubations with
fructose-6-phosphate and over 2 days in the case of
incubations with prednisolone-21-hemisuccinate.
2.9. Statistical analysis
All results were subjected to a Student’s paired
t-test where relevant. All comparisons were made
with the control solution unless stated otherwise.
3. Results
3.1. Isolation of a-crystallin
The elution profile of bovine lens crystallins was
analysed. The low molecular weight a-crystallin peak
 .was pooled data not shown and as expected, was
shown to consist of a-crystallin subunits a A and aB
 .by SDS–PAGE data not shown . SDS–PAGE also
confirmed the purity of the other crystallin fractions
 .separated data not shown .
3.2. Stability of GAP-DH and GAP-DH inacti˝ation
Initially, GAP-DH incubations in triethanolamine
buffer were carried out at 378C, but the enzyme was
very labile with activity falling to just 6% of original
control enzyme activity after just 2 h. By contrast in
preliminary experiments at 328C, GAP-DH activity
fell to 78% and 62% of original control enzyme
activity after 4 and 8 h, respectively. Incubations
were, therefore, performed at 328C in triethanolamine
buffer. In sodium phosphate buffer, GAP-DH had a
five-fold lower initial activity but was stable over
many hours upon incubation at 378C. The decreased
lability of GAP-DH in sodium phosphate buffer may
be due to the fact that glycerate diphosphate is in-
volved in the catalytic cycle of this enzyme in the
gluconeogenic direction, binding at the active site.
Direct binding could stabilise the enzyme. So far the
existence of a separate inorganic phosphate binding
site is a matter of discussion although it has been
suggested that the binding of substrate phosphate as
well as that of inorganic phosphate in the course of
w xphosphorolysis may occur at the same site 37 . This
would also explain the low initial activity of GAP-DH
in sodium phosphate buffer as phosphate ions could
effectively inhibit catalysis.
4. Inactivation by sugars and sugar phosphates
Fructose 6-phosphate at concentrations of 1 and
5 mM inactivated GAP-DH in a rapid dose-dependent
  ..manner Fig. 1 A . The different extents of inactiva-
tion were found to be statistically significant by a
Student’s t-test after 2, 4 and 8 h of incubation of
GAP-DH with 5 mM fructose 6-phosphate and after 4
and 8 h of incubation with 1 mM fructose 6-phos-
phate. Only 35% of control enzyme activity remained
 .after 2 hours of incubation of GAP-DH Ps0.014
with 5 mM fructose 6-phosphate compared to 80% of
control enzyme activity in the incubation containing
 .1 mM fructose 6-phosphate Ps0.103 . After 8 h,
only 9% of control activity remained upon incubation
 .with 5 mM fructose 6-phosphate P-0.001 , whereas
60% of control enzyme activity remained in the
1 mM fructose 6-phosphate containing solution Ps
.0.017 .
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Incubations were carried out with GAP-DH
 .  .0.2 mgrml and fructose 6-phosphate 1 and 5 mM
 .with or without a-crystallin 1 mgrml over 4 h. This
represents a stoichiometry of around 1:1. In previous
experiments, a-crystallin has been able to protect
against enzyme inactivation at a stoichiometry of one
aggregate to between one and seven enzyme
w xmolecules 21–24 . Crystallin was unable to protect
 .Fig. 1. A GAP-DH was incubated in the absence, or presence of
 .  .1 mM ’ or 5 mM % fructose 6-phosphate at 328C in 0.1 M
triethanolamine buffer, pH 7.6. The % of control enzyme activi-
 .ties of solutions were assayed over 8 h. B . GAP-DH was
 .incubated in the absence of, or presence of 1 mM ’ or 5 mM
 .% fructose 6-phosphate at 328C in 0.1 M triethanolamine buffer,
pH 7.6 and assayed. a-Crystallin was also present at 1 mgrml in
 .  .other solutions containing GAP-DH and 1 mM D or 5 mM =
fructose 6-phosphate. The % of control enzyme activities of
solutions were assayed at the same time intervals over 4 h.
Fig. 2. GAP-DH was incubated in the absence of, or presence of
 .  .10 mM fructose l , 10mM glucose 6-phosphate = or 10mM
 .glucose O at 328C in 0.1 M triethanolamine buffer, pH 7.6. The
% of control enzyme activities of solutions were assayed over
24 h.
against fructose 6-phosphate-induced GAP-DH inac-
  ..tivation Fig. 1 B . Fructose, glucose and glucose
6-phosphate at a concentration of 10 mM all failed to
significantly inactivate GAP-DH over 8 h of incuba-
 .tion data not shown .
When the incubation period was increased to 24 h,
inactivation was found to be statistically significant
in the GAP-DH solution containing either 10 mM
 .fructose or glucose 6-phosphate Fig. 2 . 81% of
 .control activity remained after 16 h Ps0.045
 .falling to 71% after 24 h Ps0.031 of incubation
with 10 mM fructose. By 24 h, 77% of control activ-
ity remained after incubation with 10 mM glucose
 .6-phosphate Ps0.041 . Glucose failed to inactivate
 .GAP-DH over a 24 h incubation period Fig. 2 .
These observations of more rapid inactivation when
GAP-DH was incubated with sugar phosphates or
fructose than with glucose are consistent with the
observed lower reactivity of glucose with proteins
w xcompared to other sugars 38 .
4.1. Inacti˝ation by prednisolone-21-hemisuccinate
and potassium cyanate
Prednisolone-21-hemisuccinate was chosen as the
glucocorticoid to study the effect of steroid-induced
inactivation because its hemisuccinate group helps
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solubilise this compound whereas most relevant
steroids are insoluble in aqueous buffers. The gluco-
corticoid prednisolone-21-hemisuccinate rapidly inac-
 .tivated GAP-DH Fig. 3 . Inactivation was found to
be statistically significant after just 2 h of incubation.
Only 70% of GAP-DH activity remained after 2 h of
incubation with 2 mM prednisolone-21-hemisuccinate
 .  .Ps0.006 falling to 30% after 8 h P-0.001 .
a-Crystallin and the aspirin-like analgesics were un-
able to protect against this glucocorticoid-induced
 .inactivation data not shown . In the case of coin-
cubation with the aspirin-like analgesics, aspirin and
ibuprofen, inactivation proceeded much more rapidly
than in the GAP-DH solution containing just pred-
 .nisolone-21-hemisuccinate data not shown .
 .Potassium cyanate 10 mM inactivated GAP-DH
after an incubation period of 8 h. 76% of control
 .GAP-DH activity remained after 8 h Ps0.003 of
 .incubation with 10 mM potassium cyanate Fig. 3 .
When the incubation period was extended to 24 h
 .data not shown , 53% of control activity remained
 . by 16 h P-0.001 falling to 23% by 24 h P-
.0.001 .
4.2. Rapid inacti˝ation by the aspirin-like analgesics
As increased inactivation of GAP-DH occurred
when it was incubated with prednisolone-21-hemi-
succinate in the presence of aspirin or ibuprofen, the
Fig. 3. GAP-DH was incubated in the absence of, or presence of
 .2 mM prednisolone-21-hemisuccinate B or 10 mM potassium
 .cyanate D at 328C in 0.1 M triethanolamine buffer, pH 7.6. The
% of control enzyme activities of solutions were assayed over
8 h.
Fig. 4. GAP-DH was incubated in the absence of, or presence of
 .  .10 mM aspirin I , 10 mM ibuprofen = or 10 mM paracetamol
 .D at 328C in 0.1 M triethanolamine buffer, pH 7.6. The % of
control enzyme activities of solutions were assayed over 4 h.
direct effect of these compounds on GAP-DH activity
 .was investigated Fig. 4 . After 2 h only 39% and
41% of control enzyme activity remained in incuba-
tions with 10 mM aspirin and ibuprofen, respectively
 .P-0.001, in both cases . By 4 h GAP-DH activity
had fallen further to 23% and 19% of control activity
after incubation with 10 mM aspirin and ibuprofen,
 .respectively. Paracetamol 10 mM inactivated GAP-
DH much less rapidly, activity falling to 76% of that
 .of the control by 4 h P-0.001 . Experiments car-
ried out in a higher strength 250 mM triethanolamine
buffer produced nearly identical results and the pH of
solutions with or without the aspirin-like analgesics
did not vary by more than 0.07 of a pH unit demon-
strating that the rapid inactivation of GAP-DH by the
aspirin-like analgesics was not due to the acidity of
these compounds.
4.3. Effect of temperature and buffer on inacti˝ation
In previous experiments, a-crystallin was shown
to fully protect catalase against glucocorticoid-in-
w xduced inactivation at 378C 24 . To test whether
protection by a-crystallin in such a system was tem-
perature-dependent, we repeated these experiments at
328C. However, no significant temperature-dependent
decrease in protection against prednisolone-21-hemi-
succinate induced inactivation was observed when
catalase was incubated with a-crystallin at 328C data
. w xnot shown as opposed to 378C 24 .
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To test whether the temperature or buffer used had
an effect on chaperone activity we carried out incuba-
tions as previously described with the exception that
they were carried out at 378C in 100 mM sodium
phosphate buffer, pH 7.6. In sodium phosphate buffer,
GAP-DH activity is less labile than in tri-
ethanolamine buffer, however, the enzyme has a
five-fold lower initial activity.
Inactivation of GAP-DH by fructose 6-phosphate
and prednisolone-21-hemisuccinate still occurred but
at a reduced rate in sodium phosphate buffer. Fruc-
 .Fig. 5. A GAP-DH was incubated in the absence of, or presence
 .of 5 mM fructose 6-phosphate % or 2 mM prednisolone-21-
 .hemisuccinate B at 378C in 0.1 M sodium phosphate buffer, pH
7.6. The % of control enzyme activities of solutions were assayed
 .over 8 h. B GAP-DH was incubated in the absence of, or
 .presence of 10 mM fructose l , 10 mM glucose-6-phosphate
 .  .  .= , 10 mM glucose O or 10 mM potassium cyante D at 378C
in 0.1 M sodium phosphate buffer, pH 7.6. The % of control
enzyme activities of solutions were assayed over 8 h.
 .tose 6-phosphate 5 mM inactivated GAP-DH by
 . 27% after 2 h P-0.003 increasing to 74% P-
.   ..0.001 after 8 h Fig. 5 A . Prednisolone-21-hemi-
 .succinate 2 mM inactivated GAP-DH by 24% after
 .  .8 h P-0.01 increasing to 65% Ps0.0015 by
 .24 h data not shown . a-Crystallin failed to confer
statistically significant protection against either fruc-
tose 6-phosphate- or prednisolone-21-hemisuccinate-
 .induced inactivation data not shown in sodium
phosphate buffer.
Glucose failed to inactivate GAP-DH significantly
  ..over 8 h Fig. 5 B consistent with the results ob-
 .tained in triethanolamine buffer Fig. 2 . Inactivation
of GAP-DH by fructose and glucose 6-phosphate was
 .  .40% P-0.0001 and 22% Ps0.0017 , respec-
  ..tively after 8 h Fig. 5 B . Potassium cyanate inacti-
 .vated GAP-DH only after 24 h by 54% Ps0.0047 .
Inactivation of GAP-DH by fructose and glucose
6-phosphate was, thus, statistically significant after
  ..just 8 h in sodium phosphate buffer Fig. 5 B ,
whereas inactivation in triethanolamine buffer was
only significant after 16 and 24 h, respectively Fig.
.2 .
4.4. In˝estigation of complex formation by HPLC
In previous work, we had noted that protection by
a-crystallin against steroid-induced inactivation of
catalase or fructose-induced inactivation of glu-
tathione reductase was not associated with formation
of a stable high molecular weight complex. This led
us to investigate whether lack of protection in our
GAP-DH inactivation system was due to formation of
a high molecular weight complex between the en-
zyme and a-crystallin. Upon inactivation by either
  ..fructose 6-phosphate Fig. 6 A or prednisolone-21-
  ..hemisuccinate Fig. 6 B tetrameric GAP-DH was
lost from the soluble fraction as measured by HPLC
suggesting inactivation by sugars and steroids is asso-
ciated with an increased insolubilisation of the GAP-
DH enzyme. The extent of this insolubilisation in-
creased with time in parallel to GAP-DH inactivation
 .data not shown . This increased insolubility was
confirmed by measuring the turbidity of these solu-
 .tions at 360 nm over time data not shown . No high
 .molecular mass HMM complex between a-crystal-
lin and GAP-DH was seen to develop with time upon
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 .incubation with either fructose 6-phosphate Fig. 7
 .or prednisolone-21-hemisuccinate data not shown
and the a-crystallin peak did not shift to an earlier
elution time suggesting that no soluble complex for-
mation between a-crystallin and GAP-DH had taken
place. Even in the presence of a-crystallin, soluble
tetrameric GAP-DH was increasingly lost with time
 .upon incubation with fructose 6-phosphate Fig. 7 or
 .Fig. 6. A HPLC analysis of solutions incubated for 8 h at 378C
in 0.1 M sodium phosphate buffer, pH 7.6 containing 1 mgrml
 .GAP-DH in the absence or presence of 5 mM fruc-
 .tose 6-phosphate – – – . The incubation solution containing
5 mM fructose 6-phosphate was 65% inactivated compared to the
 .control after 8 h of incubation. B . HPLC analysis of solutions
incubated for 1 day at 378C in 0.1 M sodium phosphate buffer,
 .pH 7.6 containing 1 mgrml GAP-DH in the absence
 .or presence of 2 mM prednisolone-21-hemisuccinate – – – . The
incubation solution containing 2 mM prednisolone-21-hemisuc-
cinate was 62% inactivated compared to the control after 1 day of
incubation.
Fig. 7. HPLC analysis of a solution incubated at 378C in 0.1 M
sodium phosphate buffer, pH 7.6 containing 1 mgrml GAP-DH,
5 mM fructose 6-phosphate and 3 mgrml a-crystallin after 0 h
 .  .  ., 8 h – – – and 1 day P P P of incubation.
 .prednisolone-21-hemisuccinate data not shown . The
slight decrease in a-crystallin concentration that is
seen may be related to the effect of fructose 6-phos-
phate or prednisolone-21-hemisuccinate on a-crystal-
lin in the presence of the enzyme. Incubation of
fructose 6-phosphate or prednisolone-21-hemisuc-
cinate with a-crystallin alone failed to insolubilse
a-crystallin over 24 h. When GAP-DH was also pre-
sent, turbidity increased slightly over 24 h, as mea-
 .sured at 360 nm data not shown .
5. Discussion
Rabbit GAP-DH was found to be very labile at
378C in our in-vitro system. In-vivo, GAP-DH stabil-
ity may require the presence of other molecules,
including perhaps free reduced glutathione, which is
present at relatively high levels in most cells, or
molecular chaperones.
Fructose 6-phosphate rapidly inactivated GAP-DH
in-vitro. Fructose and the sugar phosphate glucose
6-phosphate inactivated much less rapidly. All three
of these compounds are produced during glucose
metabolism. In the diabetic rat, sugar and sugar phos-
phate levels increase at an early stage before the first
w xopacities are manifest 39,40 . At a later stage, en-
zyme activities are reduced. An increase in lens
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protein sugar adducts is seen in human diabetic lenses
w xcompared to non diabetic lenses 10 . Rabbit muscle
GAP-DH was itself found in a glycated form resolv-
able from the native enzyme, and the glycated en-
zyme was found to have a reduced specific activity
w x41 . Muscle GAP-DH activity was also reduced after
incubation with carbamyl phosphate which paralleled
w xan increase in the formation of carbamyl protein 42 .
A unifying mechanism by which environmental
cataracts may develop could be by accelerated post-
translational modification of lenticular proteins that
occurs upon exposure of the lens to increasing con-
centrations of reactive molecules such as sugars,
cyanates and steroids, that occur with the onset of
diabetes, renal failure and with the use of glucocorti-
coid therapy, respectively. Sugar levels are seen to
rise at an early stage in experimental glucocorticoid-
w xinduced cataract 43 . Glucocorticoid-protein adducts
were detected in the lenses of patients who had
w xundergone glucocorticoid therapy 11 . Glucocorti-
coids or sugars at unphysiological levels may play a
major role in the complications of other diseases in
nucleated tissues if protein renewal is unable to keep
pace with post-translational modification.
Incubation of GAP-DH with putative anti-cataract
agents led to its rapid inactivation. Inactivation by
aspirin may be due to direct reaction of it with
GAP-DH. Aspirin can acetylate lens proteins in-vitro
w x29 . However, the way in which ibuprofen and
paracetamol inactivated GAP-DH is open to debate
as only metabolites have been shown to bind to lens
w x w xproteins in-vitro 44 . Blakytny and Harding 33 and
w xHeath et al. 22 found partial protection against the
sugar-induced inactivation of glutathione reductase
and malate dehydrogenase, respectively. Ibuprofen
conferred no protection against sugar-induced inacti-
w xvation of malate dehydrogenase 22 . However, the
aspirin-like analgesics rapidly inactivated fumarase
 .Jones and Harding, unpublished data . The mecha-
nism of the protective effect of aspirin-like analgesics
against cataract is still an open question. The results
presented in this communication show that it is not
by protection of GAP-DH, although earlier results
show a small protection of other enzyme activities.
a-Crystallin has been found to protect against
w xinactivation of enzymes in-vitro 21–24 but was
unable to protect GAP-DH against such insults. This
failure of a-crystallin to protect GAP-DH against
inactivation may be expected to be due in part to a
temperature-dependent chaperone effect. Raman et al
found that a-crystallin conferred very little protection
against insulin B chain aggregation at room tempera-
ture, but chaperone activity was found to be tempera-
ture-dependent, increasing rapidly at higher tempera-
w xtures between 308C and 408C 19 . In previous exper-
iments, a-crystallin was shown to fully protect cata-
lase against glucocorticoid-induced inactivation at
w x378C 24 . In this paper, we have shown that protec-
tion by a-crystallin in such a system is not tempera-
ture-dependent. We also explored the possibility that
protection by a-crystallin may be dependent on the
buffer system used for our incubations. Previous
incubations of enzymes had been performed in sodium
phosphate buffer. In sodium phosphate buffer, al-
though the initial activity of GAP-DH solution was
reduced, the enzyme was more stable than it is in
triethanolamine buffer allowing incubations to be
performed at 378C. Even when incubations were
carried out in sodium phosphate buffer, no significant
protection by a-crystallin against GAP-DH inactiva-
tion was observed. The rates of inactivation of GAP-
DH by fructose 6-phosphate and especially pred-
nisolone-21-hemisuccinate occurred more slowly in
the sodium phosphate buffer system compared to the
triethanolamine system. The lack of protection by
a-crystallin was not associated with formation of a
high molecular weight complex as judged by HPLC.
In other work, we have observed that no GAP-DH
activity is detected in HMM or a-crystallin fractions
isolated by size exclusion from soluble lens ho-
mogenates, but is concentrated exclusively in an ac-
tivity peak towards the end of the b elution peakH
 .Hook and Harding, unpublished data . Inactivation
of GAP-DH by fructose 6-phosphate or prednisolone-
21-hemisuccinate was seen to be associated with a
decrease in the amount of soluble tetrameric enzyme
compared to the control solution.
These results suggest that GAP-DH may be an
enzyme that a-crystallin is unable to protect against
the effect of post-translational inactivation. Perhaps
the lens compensates for the increased susceptibility
of GAP-DH to post-translational modification and
inactivation by having high levels of the enzyme or
of reduced glutathione. Indeed reduced glutathione
inhibited the modification of lens proteins by glu-
w xcosamine in-vitro 45 . Putative anti-cataract agents,
( )D.W.A. Hook, J.J. HardingrBiochimica et Biophysica Acta 1362 1997 232–242 241
aspirin and ibuprofen, rapidly inactivated GAP-DH.
GAP-DH contains a highly conserved and reactive
w xlysine near its active site 46 . Reaction of this residue
with a small molecule could lead directly to its
inactivation. a-Crystallin did not protect GAP-DH
against sugar- or steroid-induced inactivation in ex-
periments described in this communication whereas it
has fully protected a range of other enzymes against
w xsuch inactivation 21–24 . It is possible that inactiva-
tion of these other enzymes was due to cumulative
post-translational modifications inducing conforma-
tional changes that affected the active site and re-
sulted in their inactivation. a-Crystallin may have
protected against the inactivation of these enzymes
by stabilising the enzyme, whereas, GAP-DH con-
tains a reactive lysine residue which is close to the
active site cysteine residue, which forms an acyl
intermediate with the substrate glyceraldehyde 3-
w xphosphate during catalysis 47 . Acetyl phosphate
acetylated the active site cysteine residue and the
acetyl group was transferred to lysine 182. It is
possible that aspirin could inactivate GAP-DH in a
similar manner. Thus, post-translational modification
of lysine 182 could potentially compromise the func-
tional capacity of the active site, leaving a-crystallin
powerless to prevent its inactivation. Our HPLC anal-
ysis confirmed that soluble tetrameric GAP-DH was
lost rapidly in parallel to its inactivation, even in the
 .presence of a-crystallin Fig. 7 . This is in contrast to
similar previous experiments with catalase and glu-
tathione reductase, where the additional presence of
a-crystallin helped retain a significant proportion of
these oligomeric enzymes in their active soluble forms
for many days, whereas, in the absence of a-crystal-
lin these enzymes were rapidly and increasingly lost
from the soluble fraction with time, upon incubation
w xwith sugar or steroid 24,48 . The inactivation of
GAP-DH by a variety of small molecules in-vitro as
has been demonstrated in this communication may
have implications for GAP-DH modification in-vivo.
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